Ketamine For Suicidal Ideation

Completed · Phase 4

Conditions studied: Suicidal Ideation

In brief

This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).

Key facts

Study ID

NCT01507181

Run by

James Murrough

People needed

24

Starts

2012-01-01

Expected to finish

2014-09-01

Last updated by the study team

2017-02-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• English speaking Male or female patients, 18-80 years
• Patients have voluntarily admitted themselves to an inpatient psychiatric unit at MSH or, regarding the outpatient population, have clinically significant suicidal ideation without intent to harm themselves
• Women of childbearing potential must have a negative pregnancy test
• Clinically significant suicidal ideation and score of ≥4 on MADRS item 10 for suicidality
• Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document

You may not qualify if…

• Lifetime history of schizophrenia or other primary psychotic disorder
• Current presence of psychotic symptoms
• Lifetime history of a clearly established psychotic episode
• Established diagnosis of Schizoid, Schizotypal or Paranoid personality disorder
• Urine toxicology screen positive for drugs of abuse on admission
• Substance abuse or dependence within the preceding 1 month
• Anticipated discharge within 7 days of study enrollment (for patients in the inpatient arm)
• Women who plan to become pregnant, are pregnant or are breast-feeding
• Concurrent course of electroconvulsive therapy (ECT)
• Any unstable medical illness including hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease
• Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG
• The presence of any known or suspected contraindications to midazolam or ketamine including, but not limited to, known allergic reactions to these agents or acute intermittent porphyria
• Uncontrolled hypertension, defined as BP systolic >160 or BP diastolic >100 on medications
• Arrhythmia requiring medication
• Severe coronary artery disease, defined as Canadian Cardiovascular Status III or IV

Where it is running

• Icahn School of Medicine at Mount Sinai — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.